Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preprandial versus postprandial insulin Aspart in children with type 1 diabetes
IRCT20210221050444N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of insulin aspart in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: fasting blood sugar, 2-hour postprandial blood sugar and 1 more. Started Jan 2022; status: completed.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on IRCT20210221050444N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210221050444N1.